Local treatment of malignant brain tumors using implantable chemotherapeutic polymers

Research output: Contribution to journalArticle

Abstract

Malignant gliomas are among the most devastating human cancers. The infiltrating nature of these malignancies makes complete surgical resection nearly impossible. Conventional therapy for malignant gliomas consists primarily of surgical debulking followed by radiation therapy and possibly chemotherapy. The major factor limiting intracranial therapeutic levels of systemically administered chemotherapeutics is the physiologic barriers of the brain. This has led to the development of novel methods of drug delivery such as implantable polymers containing chemotherapeutic agents. Several phase III clinical trials show that implantation of carmustine-containing biodegradable polymers prolongs survival in patients with both recurrent and newly diagnosed malignant gliomas. In this article, we summarize these trials and discuss ongoing clinical trials involving implantable chemotherapy-containing polymers in the treatment of patients with malignant gliomas.

Original languageEnglish (US)
Pages (from-to)721-728
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume3
Issue number5
DOIs
StatePublished - Sep 2005

Keywords

  • Brain tumor
  • Carmustine
  • Chemotherapy
  • Drug delivery
  • Gliadel®
  • Glioblastoma
  • Glioma
  • Polymer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Local treatment of malignant brain tumors using implantable chemotherapeutic polymers'. Together they form a unique fingerprint.

Cite this